News
Delhi’s APAC Biotech bags patent for personalized immunotherapy based cancer treatment
APCEDEN – APAC’s immunotherapy product, has already been approved by the Indian FDA for treating cancer. The company has further announced it will conduct clinical trials for highly aggressive brain tumors
